BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 34248982)

  • 21. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling.
    Zong Z; Zou J; Mao R; Ma C; Li N; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Front Immunol; 2019; 10():1643. PubMed ID: 31379842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
    Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
    Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
    [No Abstract]   [Full Text] [Related]  

  • 24. Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy.
    Li W; Wu F; Zhao S; Shi P; Wang S; Cui D
    Cytokine Growth Factor Rev; 2022 Oct; 67():49-57. PubMed ID: 35871139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes.
    Bi S; Huang W; Chen S; Huang C; Li C; Guo Z; Yang J; Zhu J; Song L; Yu R
    Int J Biol Macromol; 2020 May; 150():261-280. PubMed ID: 32044366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
    Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
    Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
    Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
    Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
    Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
    Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.
    Liu N; Zhang J; Yin M; Liu H; Zhang X; Li J; Yan B; Guo Y; Zhou J; Tao J; Hu S; Chen X; Peng C
    Mol Ther; 2021 Jul; 29(7):2321-2334. PubMed ID: 33744468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trophoblast-secreted soluble-PD-L1 modulates macrophage polarization and function.
    Zhang YH; Aldo P; You Y; Ding J; Kaislasuo J; Petersen JF; Lokkegaard E; Peng G; Paidas MJ; Simpson S; Pal L; Guller S; Liu H; Liao AH; Mor G
    J Leukoc Biol; 2020 Sep; 108(3):983-998. PubMed ID: 32386458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.
    Zhang Y; Du W; Chen Z; Xiang C
    Exp Cell Res; 2017 Oct; 359(2):449-457. PubMed ID: 28830685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.
    Shinchi Y; Ishizuka S; Komohara Y; Matsubara E; Mito R; Pan C; Yoshii D; Yonemitsu K; Fujiwara Y; Ikeda K; Tamada K; Sakagami T; Suzuki M
    Cancer Immunol Immunother; 2022 Nov; 71(11):2645-2661. PubMed ID: 35352168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Progress in PD-1/PD-L1, PD-L2 signaling pathway and its role in host anti-tuberculosis immunity].
    Yu XW; Zhang JA; Xie JP
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 May; 47(5):485-489. PubMed ID: 38706074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
    Han Z; Wu X; Qin H; Yuan YC; Schmolze D; Su C; Zain J; Moyal L; Hodak E; Sanchez JF; Lee PP; Feng M; Rosen ST; Querfeld C
    JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer.
    Zuo B; Li T; Liu X; Wang S; Cheng J; Liu X; Cui W; Shi H; Ling C
    Clin Transl Oncol; 2023 Nov; 25(11):3188-3202. PubMed ID: 37115489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.